To include your compound in the COVID-19 Resource Center, submit it here.

Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

Cellestia Biotech AG (Basel, Switzerland) said it received Spanish regulatory approval to start an open-label Phase I/IIa trial of

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE